Novartis’ Paul Herrling And En Li On R&D Strategy In China, India And The Pacific Rim: An Interview With PharmAsia News (Part 1 of 2)
This article was originally published in PharmAsia News
Executive Summary
Novartis' Head of Corporate Research Paul Herrling and En Li, VP and head of research for Novartis Institutes for BioMedical Research Shanghai, sat down recently with PharmAsia News on the sidelines of the China 2008 Pharmaceutical R&D Summit in Shanghai to discuss Novartis' R&D plans in China and the Pacific Rim.
You may also be interested in...
Novartis Lines Up $1 Billion For China R&D
Novartis announced Nov. 3 a five-year, $1 billion investment in China, upping the ante for multinationals trying to build strong foundations in China's burgeoning R&D space
Novartis Lines Up $1 Billion For China R&D
Novartis announced Nov. 3 a five-year, $1 billion investment in China, upping the ante for multinationals trying to build strong foundations in China's burgeoning R&D space
Novartis Lines Up $1 Billion For China R&D
In-country research staff will increase over six-fold to approximately 1,000.